Literature DB >> 23823703

Tissue expression and correlation of a panel of urinary biomarkers following cisplatin-induced kidney injury.

Rebecca M Wadey1, Mark G Pinches, Huw B Jones, Daniela Riccardi, Sally A Price.   

Abstract

In recent years, there has been considerable activity to identify urinary biomarkers of nephrotoxicity as noninvasive measurements with greater sensitivity and specificity than traditional biomarkers, such as serum creatinine and blood urea nitrogen. Our study aimed to use cisplatin-treated rats to evaluate the use of immunohistochemistry directed at multiple urinary biomarkers in kidney tissue. Tissue levels were compared to urinary levels of these biomarkers to demonstrate tissue specificity and sensitivity. These techniques could also be used in studies where urine samples are not available, such as retrospective studies in drug safety testing, to demonstrate the potential utility of using these biomarkers in future preclinical or clinical studies. All of the biomarkers investigated showed either an increase (kidney injury molecule [KIM-1], osteopontin [OPN], and, clusterin) or a decrease (alpha-glutathione S-transferase and trefoil factor 3) except beta 2 microglobulin (β2MG) that showed no significant changes 5 days after 1.0 mg/kg or 2.5 mg/kg cisplatin treatment. All of the biomarkers except β2MG showed utility as tissue biomarkers, but KIM-1 and OPN expression correlated closely with urinary biomarker measurements and reflect tissue damage. Future studies are needed to determine the wider application of these two markers for detecting renal toxicity following administration of other nephrotoxicants.

Entities:  

Keywords:  biomarkers; histopathology; immunohistochemistry; renal.

Mesh:

Substances:

Year:  2013        PMID: 23823703     DOI: 10.1177/0192623313492044

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  9 in total

Review 1.  Biomarkers of Drug-Induced Kidney Toxicity.

Authors:  Benjamin R Griffin; Sarah Faubel; Charles L Edelstein
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

2.  Cisplatin nephrotoxicity in male beagle dogs: next-generation protein kidney safety biomarker tissue expression and related changes in urine.

Authors:  J E McDuffie; Y Chen; J Y Ma; S Lee; K M Lynch; D M Hamlin; L Nguyen; M Rizzolio; M Sonee; S Snook
Journal:  Toxicol Res (Camb)       Date:  2016-06-07       Impact factor: 3.524

Review 3.  Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.

Authors:  Blessy George; Melanie S Joy; Lauren M Aleksunes
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-12

4.  Sequencing of LRP2 reveals multiple rare variants associated with urinary trefoil factor-3.

Authors:  Gearoid M McMahon; Matthias Olden; Maija Garnaas; Qiong Yang; Xuan Liu; Shih-Jen Hwang; Martin G Larson; Wolfram Goessling; Caroline S Fox
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

5.  Comparison of changes in urinary and blood levels of biomarkers associated with proximal tubular injury in rat models.

Authors:  Kazunori Kuwata; Itsuko Nakamura; Mika Ide; Hiroko Sato; Satomi Nishikawa; Masaharu Tanaka
Journal:  J Toxicol Pathol       Date:  2015-06-01       Impact factor: 1.628

6.  Klotho and S100A8/A9 as Discriminative Markers between Pre-Renal and Intrinsic Acute Kidney Injury.

Authors:  Ae Jin Kim; Han Ro; Hyunsook Kim; Jae Hyun Chang; Hyun Hee Lee; Wookyung Chung; Ji Yong Jung
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

Review 7.  Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges.

Authors:  Martina Perše; Željka Večerić-Haler
Journal:  Biomed Res Int       Date:  2018-09-12       Impact factor: 3.411

8.  Predictive Nephrotoxicity Profiling of a Novel Antifungal Small Molecule in Comparison to Amphotericin B and Voriconazole.

Authors:  Nadeeka S Udawatte; Sung Wook Kang; Yue Wang; Thiruma V Arumugam; Chaminda J Seneviratne
Journal:  Front Pharmacol       Date:  2020-04-24       Impact factor: 5.810

9.  Low-Intensity Shockwave Therapy (LI-ESWT) in Diabetic Kidney Disease: Results from an Open-Label Interventional Clinical Trial.

Authors:  Sune Moeller Skov-Jeppesen; Knud Bonnet Yderstraede; Boye L Jensen; Claus Bistrup; Milad Hanna; Lars Lund
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-07-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.